Administration to a patient may result in local swelling, irritation of blood vessels or tissue, blockage of blood vessels and/or low-level allergic response to the particulate.
Risk of serious health consequences, including excessive carbon dioxide in the bloodstream (hypercapnia) and increased acidity in the blood (acidosis), which could lead to death.
Administration of a glass particulate, if present in an intravenous drug, may result in local irritation or swelling, and blockage or clotting in blood vessels, which may be life-threatening if a critical organ is affected.
Topical administration of a product with B. cepacia may cause serious, life-threatening infections in patients whose bodies cannot fight disease or in hospitalized patients, as well as certain other patient groups.
Ventilator shutdown may cause serious adverse health consequences, including death.
Use associated with disabling and potentially permanent side effects of the tendons, muscles, joints, nerves, and central nervous system that can occur together in the same patient.
L'Agenzia Italiana del Farmaco rende disponibili nuove e importanti
informazioni di sicurezza relative ai medicinali Arcoxia/Algix/Tauxib/Exinef (etoricoxib).
L'Agenzia Italiana del Farmaco rende disponibili nuove e importanti
informazioni di sicurezza relative ai medicinali Arcoxia/Algix/Tauxib/Exinef (etoricoxib).
Administration of a drug product intended to be sterile that is compromised can result in health hazards including risk of serious infection or other complications.
Risk of surgical intervention to retrieve a separated segment, or other serious adverse health consequences such as internal organ injury, stroke, kidney failure, intestinal failure, and death.
80.211.154.110
